Share-Based Payments (Tables)

6 Months Ended

Jun. 30, 2016

The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:



	For the Three Months Ended June 30,						For the Six Months Ended June 30,
(In millions)	2016			2015			2016			2015
Research and development	$	21.5		$	22.1		$	42.9		$	57.5
Selling, general and administrative	28.7			26.2			63.4			81.8
Restructuring charges	—			—			(1.8		)	—
Subtotal	50.2			48.3			104.5			139.3
Capitalized share-based compensation costs	(4.4		)	(2.2		)	(7.5		)	(5.6		)
Share-based compensation expense included in total cost and expenses	45.8			46.1			97.0			133.7
Income tax effect	(12.7		)	(12.9		)	(27.9		)	(39.6		)
Share-based compensation expense included in net income attributable to Biogen Inc.	$	33.1		$	33.2		$	69.1		$	94.1

The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:



	For the Three Months Ended June 30,						For the Six Months Ended June 30,
(In millions)	2016			2015			2016			2015
Market stock units	$	7.9		$	9.1		$	21.3		26.1
Time-vested restricted stock units	33.9			31.8			64.0			63.7
Cash settled performance units	4.6			3.2			4.8			27.0
Performance units	1.3			1.2			8.2			14.4
Employee stock purchase plan	2.5			3.0			6.2			8.1
Subtotal	50.2			48.3			104.5			139.3
Capitalized share-based compensation costs	(4.4		)	(2.2		)	(7.5		)	(5.6		)
Share-based compensation expense included in total cost and expenses	$	45.8		$	46.1		$	97.0		$	133.7

The following table summarizes our equity grants to employees, officers and directors under our current stock plans:



	For the Six Months Ended June 30,
	2016	2015
Market stock units	166,000	179,000
Cash settled performance shares	86,000	115,000
Performance units	56,000	89,000
Time-vested restricted stock units	594,000	375,000